Bristol Myers Squibb (CELG-RI) Other Accumulated Expenses (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Other Accumulated Expenses for 16 consecutive years, with $13.5 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Other Accumulated Expenses fell 22.5% year-over-year to $13.5 billion; the TTM figure through Jun 2026 stood at $13.5 billion (down 22.5% YoY), while the FY2025 annual figure was $17.6 billion, down 3.01% from the prior year.
• Other Accumulated Expenses rose to $13.5 billion in Q2 2026 per CELG-RI's latest filing, from $12.6 billion in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $19.3 billion in Q3 2025 and bottomed at $12.4 billion in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $15.4 billion across 5 years, with a median of $15.5 billion in 2023.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses gained 22.48% — and 2026, when it declined 23.6%.
• Bristol Myers Squibb's Other Accumulated Expenses stood at $14.6 billion in 2022, then advanced by 8.9% to $15.9 billion in 2023, then gained by 14.11% to $18.1 billion in 2024, then retreated by 3.01% to $17.6 billion in 2025, then retreated by 23.36% to $13.5 billion in 2026.
• Business Quant data shows CELG-RI's Other Accumulated Expenses at $13.5 billion in Q2 2026, $12.6 billion in Q1 2026, and $17.6 billion in Q4 2025.